Could a common diabetes drug protect aging brains in MS?

NCT ID NCT06463743

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study is testing whether metformin, a common diabetes drug, can safely protect the nervous system in people aged 55 to 75 with multiple sclerosis (MS). Thirty participants will receive either metformin or a placebo for 9 months, and researchers will use brain scans to measure nerve health. The goal is to see if metformin can slow age- and MS-related brain damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

metformin

What this could lead to

If it works, this could point toward a new way to protect the brain from age- and MS-related damage in older patients.

What could go wrong

This is a small, early pilot study with only 30 participants, so results may not apply to everyone. Metformin may also cause side effects like stomach upset.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • UBMD Neurolgy

    RECRUITING

    Buffalo, New York, 14203, United States